

Prof. Dr. med. Martin Laimer, Dr. med. Tobias Welponer, Dr. med. Christine Prodingner

Epidermolysis bullosa – eine Multisystemerkrankung mit erhöhtem Tumorrisiko

Bibliografie

- ¹ Mellerio J, et al.: Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines. *Br J Dermatol* 2016; 174: 56–67.
- ² Eisemann N, et al.: Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence. *J Invest Dermatol* 2014; 134: 43–50.
- ³ Madan V, et al.: Non-melanoma skin cancer. *Lancet* 2010; 375: 673–85.
- ⁴ Lomas A, et al.: A systematic review of worldwide incidence of nonmelanoma skin cancer. *Br J Dermatol* 2012; 166: 1069–1080.
- ⁵ Fine JD, et al.: Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986–2006. *J Am Acad Dermatol* 2009; 60(2): 203–211.
- ⁶ Montaudié H, et al.: Inherited epidermolysis bullosa and squamous cell carcinoma: a systematic review of 117 cases. *Orphanet J Rare Dis* 2016; 11(1): 117.
- ⁷ Fine JD, et al.: Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. *J Am Acad Dermatol* 2014; 70: 1103–1126.
- ⁸ Laimer M, et al.: Hereditary epidermolysis bullosa. *JDDG* 2015; 13: 1125–1133.
- ⁹ Fine JD, et al.: Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues. *J Am Acad Dermatol* 2009; 61: 367–384.
- ¹⁰ Fine JD, et al.: Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs. *J Am Acad Dermatol* 2009; 61(3): 387–402.
- ¹¹ Kim M, et al.: Update on the pathogenesis of squamous cell carcinoma development in recessive dystrophic epidermolysis bullosa. *Eur J Dermatol* 2015; 25(Suppl 1): 30–32.
- ¹² Cianfarani F, et al.: Pathomechanisms of Altered Wound Healing in Recessive Dystrophic Epidermolysis Bullosa. *Am J Pathol* 2017; 187: 1445–1453.
- ¹³ Föll MC, et al.: Identification of tissue damage, extracellular matrix remodeling and bacterial challenge as common mechanisms associated with high-risk cutaneous squamous cell carcinomas. *Matrix Biol* 2018; 66: 1–21.
- ¹⁴ Mohr EB, et al.: Multiple squamous cell carcinomas in junctional epidermolysis bullosa: a surgical challenge. *Dermatol Surg* 2008; 34: 1131–1136.
- ¹⁵ Alter M, et al.: Treatment of advanced cutaneous squamous cell carcinomas with epidermal growth factor receptor inhibitors. *Dermatology* 2013; 227: 289–294.
- ¹⁶ Kim M, et al.: Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma. *Br J Dermatol* 2013; 169: 208–210.
- ¹⁷ Stratigos A, et al.: Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. *Eur J Cancer* 2015; 51: 1989–2007.
- ¹⁸ Migden MR, et al.: PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. *N Engl J Med* 2018; 379: 341–351.
- ¹⁹ Medek K, et al.: Wound healing deficits in severe generalized recessive dystrophic epidermolysis bullosa along anticancer treatment with cetuximab. *JDDG* 2019; 17: 448–450.